CisplatinAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsPlatinumDrug Resistance, NeoplasmDrug Administration ScheduleOvarian NeoplasmsFluorouracilLung NeoplasmsCombined Modality TherapyEtoposideDNA AdductsDeoxycytidineVinblastineCell Line, TumorDrug SynergismCarboplatinDrug Screening Assays, AntitumorPaclitaxelCarcinoma, Squamous CellTumor Cells, CulturedTreatment OutcomeIfosfamideDoxorubicinVomitingDose-Response Relationship, DrugApoptosisOxonic AcidCarcinoma, Non-Small-Cell LungHead and Neck NeoplasmsCell SurvivalDrug ResistanceSurvival AnalysisTegafurInfusions, IntravenousTaxoidsAdenocarcinomaCamptothecinCarcinoma, Small CellNauseaDNA DamageMitomycinDisease-Free SurvivalSurvival RateLeukopeniaStomach NeoplasmsBleomycinNeutropeniaNeoplasm StagingAntineoplastic Agents, PhytogenicInfusions, Intra-ArterialTesticular NeoplasmsDNA RepairDrug EvaluationVindesineEsophageal NeoplasmsMice, NudeGlutathioneMesotheliomaHyperthermia, InducedAntimetabolites, AntineoplasticThiosulfatesChemotherapy, AdjuvantCarcinomaNeoplasms, Germ Cell and EmbryonalNeoplasm Recurrence, LocalTumor Suppressor Protein p53ThrombocytopeniaMaximum Tolerated DoseNeoplasmsOsteosarcomaRemission InductionGerminomaCarmustineRadiation-Sensitizing AgentsInhibitory Concentration 50KidneyGene Expression Regulation, NeoplasticXenograft Model Antitumor AssaysDrug CombinationsAntiemeticsTime FactorsCyclophosphamideEpirubicinCation Transport ProteinsMethotrexatePleural NeoplasmsUrologic NeoplasmsVincristineHepatoblastomaUterine Cervical NeoplasmsPeritoneal NeoplasmsBlood Urea NitrogenCross-Linking ReagentsOndansetronCell CycleAmifostineFeasibility StudiesRadiotherapy DosageGuanine